rituximab,lenalidomide
Not Tagged
['lenalidomide', 'lymphoma', 'lymsm', ' lena', 'hodgkin', 'ritux', 'augment,trial']
the 5-year follow-up of the phase 3 augment trial found enhanced progression-free survival when lenalidomide plus rituximab was used to treat patients with relapsed/refractory indolent non-hodgkin lymphoma. #lymsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.